Merck & Co., Inc. (NYSE:MRK) Posts Earnings Results, Beats Expectations By $0.40 EPS

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Thursday. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40, FiscalAI reports. The firm had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 EPS.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Third-quarter revenue rose 5% to $18.1 billion, while Merck raised the midpoint of its 2026 revenue and EPS guidance to $66.8–$67.3 billion and $2.77–$2.82, respectively.
• Newer products continued to gain traction, including WINREVAIR, whose sales increased 94% to $694 million, and WELIREG, up 58% to $307 million; KEYTRUDA sales also grew 6% to $8.6 billion.
• Management highlighted encouraging pipeline progress, including positive phase III data for sac-TMT in endometrial cancer, favorable results for the individualized cancer vaccine intismeran in melanoma, and positive phase IIb data for tulisokibart in hidradenitis suppurativa.
• Management expects more than $2 billion of 2027 revenue headwinds from generic competition and loss of exclusivity affecting BRIDION, the JANUVIA family, and A??DEMPAS, while KEYTRUDA growth is expected to moderate ahead of its eventual loss-of-exclusivity period.
• Merck expects 2027 to be another investment year, with operating expenses rising at a mid- to high-single-digit rate as it funds launches and pipeline development; vaccine utilization trends, pricing pressure outside the U.S., and policy changes in Germany remain areas to monitor.

Merck & Co., Inc. Trading Up 3.8%

MRK stock traded up $5.39 during trading on Thursday, hitting $146.32. The company had a trading volume of 13,434,502 shares, compared to its average volume of 9,881,721. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92. The company has a 50 day simple moving average of $146.89 and a 200-day simple moving average of $126.49. The firm has a market capitalization of $360.99 billion, a P/E ratio of 43.90, a PEG ratio of 6.49 and a beta of 0.21. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Insider Buying and Selling

In other news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last 90 days. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Beat-and-raise results supported the stock. Merck lifted its 2026 adjusted earnings outlook, helped by better performance from Keytruda—including the newer Qlex formulation—and recently launched products. The company’s sales forecast was raised to approximately $66.8 billion-$67.3 billion. MRK Q3 earnings and sales beat estimates
• Positive Sentiment: Growth from newer products is helping offset longer-term patent concerns. WINREVAIR revenue rose sharply, reaching about $694 million, while Keytruda and Qlex sales remained resilient. Investors are looking for these products to reduce Merck’s dependence on Keytruda before its expected patent-related erosion later in the decade. Merck revenue up on Keytruda and Winrevair growth
• Positive Sentiment: Oncology pipeline news improved Merck’s growth narrative. Phase 3 data showed KEYTRUDA reduced the risk of disease progression in advanced endometrial cancer, while sacituzumab tirumotecan produced positive late-stage results and received FDA priority review. These developments could expand Merck’s future cancer franchise if approvals and commercialization succeed. Merck Phase 3 endometrial cancer data and FDA review
• Neutral Sentiment: Near-term revenue quality remains mixed. Management indicated that roughly $550 million of quarterly sales benefited from customer-purchase timing, suggesting underlying growth was closer to flat. Merck also warned of generic-drug headwinds in 2027, making pipeline execution increasingly important.
• Negative Sentiment: Patent-cliff and legal risks remain overhangs. Keytruda’s eventual loss of exclusivity remains the central long-term concern, and a law firm announced an investigation into potential securities-law violations related to an October 22 disclosure. No wrongdoing has been established.

Wall Street Analyst Weigh In

MRK has been the subject of several recent analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, October 5th. Leerink Partners increased their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Morgan Stanley reduced their target price on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 7th. Citigroup raised their target price on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. Finally, HSBC increased their price objective on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Seventeen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $153.12.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.